Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

BAP1 inhibits pathogenesis. 1 / 1

| 1

➶

eidos

"More importantly , when compared to NF2 and CDKN2A double knockout tumors where BAP1 expression was retained , many of the top differentially expressed genes in triple knockout tumors were downstream targets of PRC2 , uncovering a connection between BAP1 and PRC2 and thereby confirming in vivo how , at least in part , the loss of BAP1 contributes to MPM pathogenesis [ 204 ] ."

| PMC

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...